Ditiocarb sodium (Sodium diethyldithiocarbamate) is an accelerator of the rate of copper cementation. Sodium diethyldithiocarbamate reduces the incidence of HIV infection, and also enhances adjuvant immunotherapy of high risk breast cancer.
性状
Solid
IC50 & Target[1][2]
HIV
体外研究(In Vitro)
Ditiocarb sodium (Sodium diethyldithiocarbamate) reacts with the Cu solution giving a complex of copper diethyldithiocarbamate, which enhances the rate of cementation. Ditiocarb sodium is an agent with strong antioxidant capacity and chelating activities. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Ditiocarb sodium (Sodium diethyldithiocarbamate) improves the depressed immune responses of newborn and aged mice. Sodium diethyldithiocarbamate prevents cisplatin nephrotoxicity in animals without reducing the antitumor activity. In that AIDS model, Ditiocarb sodium reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
ClinicalTrial
参考文献
[1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.[2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44.
溶解度数据
In Vitro: DMSO : 100 mg/mL (583.91 mM; Need ultrasonic)配制储备液